Skip to main content

Piramal progresses two API sites

15th June 2022

Submitted by:

Andrew Warmington

Piramal Pharma Solutions (PPS) has announced the implementation of “various tools to unlock API manufacturing capacity and support client needs in drug development and on-patent projects” at its 40-hectare site at Digwal in the Indian state of Telangana. This came shortly after its new API plant at Aurora, Ontario, came online.

The investment at Digwal is based on applying operational excellence (OE) tools, such as theory of constraint, value stream mapping, optimisation of unit operations and line balancing. In all, this has released 20% of capacity at the site, where PPS has made or committed over $30 million in capital investments, both in the infrastructure and the operational culture.

In addition, to reduce manual interventions, mechanisation initiatives are in progress at the site, including investments in powder transfer systems, and a zero liquid discharge system has been implemented. Digwal is also moving away from paper records to electronic batch records. Ongoing additions include a revamped QC lab and a new, centralised warehouse for finished goods that features a warehouse management system.

Having previously added development services for late-phase clinical requirements, registration and site transfers to support the commercial launch, PPS has added to R&D capabilities at Digwal, with some 20 new fume hoods coming online. “As a result, the site has recently partnered with clients on more than a dozen programmes, including several which have been commercially launched and others that are under registration with the regulator,” the company said.

The Aurora plant came online in May after completing its initial production runs. These have included process validation, registration and engineering campaigns. The new plant, built as part of a C$30 million capital investment at Aurora, has around 900 m2 of manufacturing space and includes two suites with glass-lined reactors of 2-4 m3 capacity, plus additional filtration and drying capabilities. It also expands the company’s ability to produce clinical- to commercial-scale APIs and HPAPIs requiring an occupational exposure limit of 1 ug/m3.

“We’ve achieved our objectives of strengthening our presence in Canada, adding API development and commercial support for other geographies such as North America and Europe, and supporting market demand for integrated solutions,” said CEO Peter DeYoung.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington